Performance of APLS Apellis Pharmaceuticals | -52% in 12m
Compare APLS with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Apellis Pharmaceuticals with its related Sector/Index XBI
Performance Duell APLS vs XBI
| TimeFrame | APLS | XBI |
|---|---|---|
| 1 Day | -10.1% | -0.17% |
| 1 Week | -0.66% | 6.87% |
| 1 Month | -18.4% | 0.03% |
| 3 Months | -34.2% | 2.68% |
| 6 Months | -7.19% | 26.46% |
| 12 Months | -52.0% | 6.41% |
| YTD | -28.4% | 0.22% |
| Rel. Perf. 1m | -1.76 | |
| Rel. Perf. 3m | -2.47 | |
| Rel. Perf. 6m | -3.03 | |
| Rel. Perf. 12m | -7.28 |
Is Apellis Pharmaceuticals a good stock to buy?
No, based on ValueRay Fundamental Analyses, Apellis Pharmaceuticals (NASDAQ:APLS) is currently (May 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -60.25 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of APLS as of May 2024 is 38.04. This means that APLS is currently overvalued and has a potential downside of -13.35% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of APLS as of May 2024 is 38.04. This means that APLS is currently overvalued and has a potential downside of -13.35% (Sold with Premium).
Is APLS a buy, sell or hold?
- Strong Buy: 11
- Buy: 4
- Hold: 3
- Sell: 0
- Strong Sell: 0
Values above 0%: APLS is performing better - Values below 0%: APLS is underperforming
Compare APLS with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -3.68% | -18.12% | -26.40% | -79.07% |
| US NASDAQ 100 | QQQ | -4.36% | -18.36% | -25.79% | -88.90% |
| US Dow Jones Industrial 30 | DIA | -3.47% | -18.38% | -22.08% | -69.82% |
| German DAX 40 | DBXD | -3.36% | -18.91% | -28.46% | -67.04% |
| UK FTSE 100 | ISFU | -3.01% | -22.59% | -23.63% | -62.69% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -2.77% | -22.26% | -8.78% | -39.85% |
| Hongkong Hang Seng | HSI | -6.46% | -27.27% | -7.54% | -37.70% |
| Japan Nikkei 225 | EXX7 | -2.93% | -15.43% | -22.79% | -71.30% |
| India NIFTY 50 | INDA | 0.18% | -17.52% | -24.61% | -77.19% |
| Brasil Bovespa | EWZ | -5.46% | -18.42% | -11.63% | -72.36% |
APLS Apellis Pharmaceuticals vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -5.19% | -17.04% | -27.96% | -91.38% |
| Consumer Discretionary | XLY | -2.31% | -17.30% | -17.68% | -73.77% |
| Consumer Staples | XLP | -2.32% | -21.83% | -20.04% | -54.62% |
| Energy | XLE | -0.33% | -14.06% | -20.40% | -72.16% |
| Financial | XLF | -2.77% | -17.13% | -30.80% | -81.50% |
| Health Care | XLV | -2.26% | -18.29% | -19.17% | -60.67% |
| Industrial | XLI | -2.99% | -17.54% | -31.27% | -79.48% |
| Materials | XLB | -3.49% | -16.59% | -27.00% | -69.11% |
| Real Estate | XLRE | -4.06% | -15.09% | -18.07% | -56.20% |
| Technology | XLK | -4.73% | -17.47% | -24.51% | -88.19% |
| Utilities | XLU | -4.86% | -24.44% | -22.74% | -56.48% |
| Aerospace & Defense | XAR | -4.36% | -20.60% | -24.67% | -77.47% |
| Biotech | XBI | -7.53% | -18.45% | -33.65% | -58.37% |
| Homebuilder | XHB | -3.74% | -15.89% | -45.15% | -101.78% |
| Retail | XRT | -3.96% | -17.54% | -28.53% | -74.23% |
Does Apellis Pharmaceuticals outperform its market, is APLS a Sector Leader?
No, over the last 12 months Apellis Pharmaceuticals (APLS) made -51.96%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.41%.
Over the last 3 months APLS made -34.18%, while XBI made 2.68%.
No, over the last 12 months Apellis Pharmaceuticals (APLS) made -51.96%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.41%.
Over the last 3 months APLS made -34.18%, while XBI made 2.68%.
| Period | APLS | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -18.42% | 0.03% | -0.30% |
| 3 Months | -34.18% | 2.68% | 4.15% |
| 12 Months | -51.96% | 6.41% | 27.11% |